Dr. The results of this trial in individuals with relapsing MS continue to build on the positive data from our 1st study and offer further clinical support for the Apitope method of the treatment of serious autoimmune conditions. Up to now this process has been shown to be impressive in experimental versions but has been sluggish to advance into the clinic. Based on these encouraging preliminary results, a second Phase I medical trial has been finished to assess the safety of ATX-MS-1467, and also biological parameters, in a complete of 43 patients with relapsing MS.Exclusively licenses the concentrated microwave thermotherapy technology from MIT. The ongoing company is rolling out the clinical thermotherapy system and is funding the current clinical studies. The Department of the Air Force funded the initial MIT Lincoln Laboratory analysis by Fenn.
AmoyDx receives SFDA approval for its BRAF and EGFR mutations recognition kits Amoy Diagnostics announced today that its EGFR and BRAF mutation recognition kits received market approval from China’s State Meals and Drug Administration . The SFDA is the proficient authority for regulating drugs and in vitro diagnostics in mainland China.